Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.
about
A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigensThe immunogenicity of a new human minor histocompatibility antigen results from differential antigen processingContribution of mass spectrometry to contemporary immunology.A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications.Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.Immunotherapy of AML: future directionsLeukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR.Pathogenesis and management of graft-versus-host disease.Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT).Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.Self peptides and the peptidic self.T-cell therapy of leukemia.Cytolytic pathways in haematopoietic stem-cell transplantation.Identification of minor histocompatibility antigens based on the 1000 Genomes ProjectAdoptive cellular therapy: a therapeutic reality?Clinical developments in reduced intensity haematopoietic stem cell transplantation.Characterization of CTL Clones Specific for Single Antigen, H60 Minor Histocompatibility Antigen.Allogeneic immune replacement as cancer immunotherapy.CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cellsAnalysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.DNA vaccines to attack cancerNonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.Dendritic cells in allogeneic hematopoietic stem cell transplantation.Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.A human minor histocompatibility antigen resulting from differential expression due to a gene deletionOptimization of allogeneic transplant conditioning: not the time for dogma.Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantationAllogeneic hematopoietic transplantation and natural killer cell recognition of missing self.Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.Immune recognition and rejection of allogeneic skin grafts.A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme.
P2860
Q24536117-7C10FF07-AA1E-4D03-9CC2-008B192BDEF8Q24673417-B5F71236-AD1D-405E-8098-8956E87C7FBCQ24675797-8E61F6B9-B9C6-4235-9F65-0D2705A628E4Q30697033-4012C6E4-F42A-406D-BE15-E0D7F1C55017Q33267303-9582D020-0DBD-4A28-A746-44AD3EA03A65Q33849560-82183E31-C790-4446-A155-5B713BE43D53Q33893052-515231B4-DE93-4DEF-BF62-32F1D9F426EBQ33931811-095A1133-401C-4F73-9366-A283786CD079Q33955292-25420DC2-2FC6-484A-B0FB-C893711E1EAEQ34077479-20B9D09D-B8C5-43E2-9211-B440BBF017B7Q34135678-22C2F964-6CF6-441D-B1B6-828869D8B7A2Q34312702-58AE139E-8A3D-4AF7-A481-B7F60CC1CC7DQ34326704-2DE9F46C-BD0D-45AE-BDD0-22EBD8DC9691Q34380578-427B9F8E-C84F-4497-A241-0CA486512B02Q34487436-8036E77E-F6D4-426A-91D8-0B77BE4983C8Q34560516-011396C1-AC6B-4877-B4A5-627B428D2A44Q34608658-F00440CD-34CB-41B7-A427-A2BFD36C30A5Q34632083-B6EABBB6-8032-46B1-8060-7453054D06E4Q34648976-01B4E7C9-ADA1-4560-A583-34A0B43709B0Q34875170-6AA51F92-DD5E-45DC-8CC9-48ABFC3597C6Q34974730-89DE362E-C135-4ED2-86AB-4C1227A9605AQ35000944-F5EF2ED4-F0FC-418C-B000-7B6768521567Q35547257-70BF5CCF-A0B6-4A67-B843-6A971CE5CE6DQ35558987-91AC91CD-F23F-4BA2-BAFA-E083161AC733Q35849500-989AA0FB-64BB-46BE-A08F-11276776DE20Q35855143-F379CD74-AB07-4B53-A151-F46A8EAF9919Q35918466-C27DAD92-5C11-4873-841A-27BF912568C6Q36007719-885A7450-8B92-4EC1-8C48-BEAA380FDC8AQ36272587-4B5D536C-E24E-4FC5-8FC5-6B35B62BA6C7Q36304574-2135C1EF-7E19-4B68-B2B9-507249087F8CQ36370375-10095B11-9690-4AC1-96C3-2A18D8BDC9AEQ36556498-344EC2F3-A89E-4CBB-A157-10E9CCDC87BAQ36556944-3C6BBB46-D16E-47C6-ADF2-DE887B77EC04Q36652207-808B0163-3FF0-40F2-B04C-C2FC8C78BBE9Q36830199-D16FB84D-7BA0-40F5-984C-A1F4FF7F93BAQ36979992-2AFB2EBB-EF35-4E36-B0B0-C97746E03525Q37678207-D41F864D-2DF2-41C7-A3CF-3A6A204E0317Q37888686-752E6470-F69C-439D-8EA3-1B245818EBBBQ38674730-75107200-9E1B-4026-AE2F-DBD72A741C7CQ38792076-5C840F72-D51F-42A5-8360-E428407EE5B8
P2860
Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Human minor histocompatibility ...... on and adoptive immunotherapy.
@en
type
label
Human minor histocompatibility ...... on and adoptive immunotherapy.
@en
prefLabel
Human minor histocompatibility ...... on and adoptive immunotherapy.
@en
P2860
P1476
Human minor histocompatibility ...... on and adoptive immunotherapy.
@en
P2093
P2860
P304
P356
10.1111/J.1600-065X.1997.TB00978.X
P577
1997-06-01T00:00:00Z